Peculiarities of the clinical course of metabolic dysfunction-associated steatotic liver disease in comorbidity with community-acquired pneumonia of medium severity
Vol 93 No 1 (2024), Therapy
Vol 93 No 1 (2024)

Peculiarities of the clinical course of metabolic dysfunction-associated steatotic liver disease in comorbidity with community-acquired pneumonia of medium severity

Therapy
https://doi.org/10.35339/ekm.2024.93.1.krm
Published March 31, 2024
O.S. Khukhlina
Bukovinian State Medical University, Chernivtsi, Ukraine
https://orcid.org/0000-0002-1086-2785
I.V. Rachynska
Bukovinian State Medical University, Chernivtsi, Ukraine
https://orcid.org/0000-0003-4517-666X
O.Ye. Mandryk
Bukovinian State Medical University, Chernivtsi, Ukraine
https://orcid.org/0000-0002-2784-4348
Ye.P. Tkach
Bukovinian State Medical University, Chernivtsi, Ukraine
https://orcid.org/0000-0001-5166-0859
PDF (Українська)

Keywords

metabolic syndrome
obesity
hepatic steatosis
biochemical syndromes

How to Cite

Khukhlina, O., Rachynska, I., Mandryk, O., & Tkach, Y. (2024). Peculiarities of the clinical course of metabolic dysfunction-associated steatotic liver disease in comorbidity with community-acquired pneumonia of medium severity. Experimental and Clinical Medicine, 93(1), 46-55. https://doi.org/10.35339/ekm.2024.93.1.krm
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The comorbidity of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Community-Acquired Pneumonia (CAP) is an important issue in modern medicine due to the wide spread of diseases among the population. MASLD is a dynamic condition that can regress to isolated steatosis with a relatively constant level of activity or cause progressive fibrosis leading to liver cirrhosis (F4 fibrosis stage). 25% of patients with MASLD develop steatohepatitis, among which 25% develop liver cirrhosis. The aim of the study was to establish the features of the clinical course of steatotic liver disease in the presence of concomitant community-acquired pneumonia. 67 patients with MASLD on the background of obesity of the 1st degree were examined: 32 patients with steatohepatitis, obesity of the 1st degree and CAP of moderate severity (group 1); 35 patients with steatohepatitis and obesity of the 1st degree (group 2). We established that the clinical course of metabolic dysfunction-associated steatotic liver disease in comorbidity with obesity and non-hospital pneumonia of moderate severity is characterized by a higher frequency and intensity of clinical syndromes compared to patients with isolated MASLD: astheno-vegetative by 2.1 times, dyspeptic – 4.4 times, abdominal pain – 8.8 times, cholestatic – 3.7 times (p<0.05). We observed that in case of the comorbid course of MASLD and CAP a frequency of biochemical syndromes was higher: cytolysis – 2.2 times, mesenchymal inflammation – 2.3 times, cholestasis – 3.9 times, hepatocellular insufficiency – in 2.9 times (p<0.05). During the comorbid course of these two diseases a higher degree of hepatic steatosis (1.4 times) was observed in comparison with the group of patients with isolated MASLD (p<0.05). The frequency of cases of S3 degree of hepatic steatosis prevailed in MASLD in comorbidity with CAP by 2.0 times (p<0.05) in comparison with the isolated course of MASLD.

Keywords: metabolic syndrome, obesity, hepatic steatosis, biochemical syndromes.

Archived: https://doi.org/10.5281/zenodo.14266086

https://doi.org/10.35339/ekm.2024.93.1.krm
PDF (Українська)

References

Chen VL, Hawa F, Berinstein JA, Reddy CA, Kassab I, Platt KD, et al. Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19. Dig Dis Sci. 2021;66(9):3192-8. DOI: 10.1007/s10620-020-06618-3. PMID: 32980956.

Herrero R, Sanchez G, Asensio I, Lopez E, Ferruelo A, Vaquero J, et al. Liver-lung interactions in acute respiratory distress syndrome. Intensive Care Med Exp. 2020;8(Suppl_1):48. DOI: 10.1186/s40635-020-00337-9. PMID: 33336286.

Borisov AN, Blum CA, Christ-Crain M, Ebrahimi F. No obesity paradox in patients with community-acquired pneumonia-Secondary analysis of a randomized controlled trial. Nutr Diabetes. 2022;12(1):12. DOI: 10.1038/s41387-022-00190-7. PMID: 35322019.

Ghilotti F, Bellocco R, Ye W, Adami HO, Trolle Lagerros Y. Obesity and risk of infections: Results from men and women in the Swedish National March Cohort. Int J Epidemiol. 2019;48(6):1783-94. DOI: 10.1093/ije/dyz129. PMID: 31292615.

Barmanray RD, Cheuk N, Fourlanos S, Greenberg PB, Colman PG, Worth LJ. In-hospital hyperglycemia but not diabetes mellitus alone is associated with increased in-hospital mortality in community-acquired pneumonia (CAP): A systematic review and meta-analysis of observational studies prior to COVID-19. BMJ Open Diabetes Res Care. 2022;10(4):e002880. DOI: 10.1136/bmjdrc-2022-002880. PMID: 35790320.

Chacko KR, Reinus J. Extrahepatic complications of nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20(2):387-401. DOI: 10.1002/hep.26717. PMID: 24002776.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. DOI: 10.1002/hep.29367. PMID: 28714183.

Golabi P, Paik JM, Eberly K, de Avila L, Alqahtani SA, Younossi ZM. Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C. Ann Hepatol. 2022;27(1):100556. DOI: 10.1016/j.aohep.2021.100556. PMID: 34800721.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.